Volume 13, Issue 1 p. 71-80
Main Paper

A practical guide to Bayesian group sequential designs

Thomas Gsponer

Corresponding Author

Thomas Gsponer

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

Correspondence to: Heinz Schmidli, Novartis Pharma AG, PO Box, CH-4002 Basel, Switzerland.

E-mail: [email protected]

Search for more papers by this author
Florian Gerber

Florian Gerber

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

Search for more papers by this author
Björn Bornkamp

Björn Bornkamp

Statistical Methodology, Novartis Pharma AG, Basel, Switzerland

Search for more papers by this author
David Ohlssen

David Ohlssen

Statistical Methodology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Search for more papers by this author
Marc Vandemeulebroecke

Marc Vandemeulebroecke

Integrated Information Sciences, Novartis Pharma AG, Basel, Switzerland

Search for more papers by this author
Heinz Schmidli

Heinz Schmidli

Statistical Methodology, Novartis Pharma AG, Basel, Switzerland

Search for more papers by this author
First published: 24 August 2013
Citations: 46
Supporting information may be found in the online version of this article.

Abstract

Bayesian approaches to the monitoring of group sequential designs have two main advantages compared with classical group sequential designs: first, they facilitate implementation of interim success and futility criteria that are tailored to the subsequent decision making, and second, they allow inclusion of prior information on the treatment difference and on the control group. A general class of Bayesian group sequential designs is presented, where multiple criteria based on the posterior distribution can be defined to reflect clinically meaningful decision criteria on whether to stop or continue the trial at the interim analyses. To evaluate the frequentist operating characteristics of these designs, both simulation methods and numerical integration methods are proposed, as implemented in the corresponding R package gsbDesign. Normal approximations are used to allow fast calculation of these characteristics for various endpoints. The practical implementation of the approach is illustrated with several clinical trial examples from different phases of drug development, with various endpoints, and informative priors. Copyright © 2013 John Wiley & Sons, Ltd.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.